Sabljic, Nikica (57221634280)Nikica (57221634280)SabljicMitrovic, Mirjana (54972086700)Mirjana (54972086700)MitrovicPantic, Nikola (57221630977)Nikola (57221630977)PanticThachil, Jecko (23029666900)Jecko (23029666900)Thachil2025-06-122025-06-122023https://doi.org/10.1055/a-2238-4782https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187701066&doi=10.1055%2fa-2238-4782&partnerID=40&md5=4f4881615664491a8c4d9c35421b10a0https://remedy.med.bg.ac.rs/handle/123456789/2912Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients. © 2024. Thieme. All rights reserved.acute promyelocytichypercoagulabilityleukemiathrombosis